This SS-31 peptide review covers elamipretide research, reported benefits, side effects, dosing practices, and what US buyers should verify before purchase.
A review of SS-31 peptide research shows that elamipretide has produced encouraging signals in small mitochondrial studies but has repeatedly missed primary endpoints in larger randomized trials. SS-31 is an experimental mitochondria-targeted tetrapeptide that is not FDA-approved for human use in the United States. This SS-31 peptide review breaks down what human trials actually measured, which side effects were reported, and what buyers should verify before ordering.
What Is SS-31 (Elamipretide)?
SS-31 is the original code name for elamipretide, a synthetic tetrapeptide made of just four amino acids: D-arginine, dimethyltyrosine, lysine, and phenylalanine amide. Its molecular weight is roughly 640 Da, and it dissolves easily in water. You will also see it sold as MTP-131, Bendavia, or Forzinity.
The peptide was designed to concentrate inside mitochondria rather than spread through the whole body. It binds to cardiolipin, a phospholipid on the inner mitochondrial membrane that supports the electron transport chain. When cardiolipin oxidizes, energy production drops and reactive oxygen species rise, so stabilizing it is the core idea behind SS-31.
Stealth BioTherapeutics has been the primary developer, and most published human data comes from company-sponsored trials in rare mitochondrial diseases, heart failure, and eye disease.
What the Human Trials Actually Found
The clinical record is mixed, and the pattern matters more than any single study. Smaller and open-label trials tend to look promising, while larger blinded trials have generally not confirmed those results.
| Trial | Population | Design | Reported Outcome |
|---|---|---|---|
| TAZPOWER | Barth syndrome | Open-label phase followed by randomized withdrawal, 40 mg subcutaneous daily | Functional improvements reported in the open-label phase; the FDA later issued a Complete Response Letter |
| MMPOWER-3 | Primary mitochondrial myopathy | Randomized, double-blind, placebo-controlled | Did not meet its primary endpoint on walking distance |
| ReCLAIM-2 | Dry age-related macular degeneration | Randomized, double-blind | Primary endpoint not met; some secondary structural measures favored treatment |
| EMBRACE-STEMI | Heart attack patients | Randomized, placebo-controlled | No significant reduction in infarct size |
A Complete Response Letter means the FDA declined to approve the drug in its submitted form; it does not mean the underlying science is worthless. Larger randomized trials of elamipretide have not confirmed the benefits seen in smaller open-label studies.
SS-31 has a credible mechanism and a weak-to-mixed clinical track record. Those two facts are not contradictory, and both belong in any balanced review.
Reported Benefits and Side Effects
Any honest discussion of ss-31 peptide benefits and side effects has to separate trial data from anecdotal reports. In controlled studies, the most common complaints were injection site reactions, itching, hives, nausea, headache, and diarrhea.
Reported ss-31 peptide side effects in published trials include:
- Injection site pain, redness, or swelling
- Pruritus and urticaria (itching and hives)
- Nausea, diarrhea, and abdominal discomfort
- Headache, dizziness, and fatigue
Most events were mild to moderate and resolved without treatment. Trials also tracked serious adverse events, and no single consistent safety signal has been established across studies. Anyone with a medical condition should discuss any peptide use with a healthcare professional first.
On the benefit side, online user reports describe better energy, less fatigue, improved exercise tolerance, and sharper cognition. No controlled trial has demonstrated those effects in healthy adults, and self-reported improvements are easily influenced by expectation.
Dosage, Reconstitution, and Nasal Spray
The most-studied clinical dose is 40 mg injected subcutaneously once daily, while hospital studies have used continuous intravenous infusions. Anecdotal protocols circulating online often suggest 1 to 5 mg per day, a fraction of the clinical dose, with no human data behind the number.
Reconstitution basics
Typical ss-31 peptide reconstitution guidance for laboratory work uses bacteriostatic or sterile water to reach a concentration of roughly 1 to 5 mg/mL. Lyophilized powder should be stored frozen, and reconstituted solution refrigerated and used within a few weeks. Freezing and thawing a reconstituted vial repeatedly degrades the peptide.
Intranasal products
ss-31 peptide nasal spray products are sold by several vendors as an alternative to injections. There is no published human trial of intranasal elamipretide, so absorption and effects are simply unknown. Peptides of this size are generally absorbed poorly through the nasal lining without an absorption enhancer.
Buying SS-31 Online in the US
Most listings for ss 31 peptide for sale online label the product as a research chemical, not a supplement or drug. Selling SS-31 for human consumption without FDA approval is illegal in the United States, even though the peptide itself is not a controlled substance.
Before ordering, verify:
- A third-party certificate of analysis showing HPLC purity of 98% or higher
- Independent laboratory verification, not a self-issued PDF
- A lot number on the vial that matches the certificate
- Cold-chain shipping and clear storage instructions
- A US-based seller with a real return address and responsive support
Price alone is not a quality signal in either direction. Many resellers publish identical marketing copy with no verifiable lab data, and a low price often reflects skipped testing.
The Bottom Line
SS-31 is a genuinely interesting molecule with solid mechanistic research behind it, but the human evidence remains mixed and no regulatory agency has approved it for any indication. People with mitochondrial conditions should ask a specialist about clinical trials rather than self-treating with gray-market vials.
Three conclusions are worth remembering on their own. SS-31 is not FDA-approved for human use in the United States. Larger randomized trials of elamipretide have not confirmed the benefits seen in smaller open-label studies. Research-grade SS-31 sold online is labeled for laboratory use only and carries no guarantee of purity, sterility, or dose accuracy.
Frequently Asked Questions
Is the SS-31 peptide FDA approved?
No. SS-31 (elamipretide) has not been approved by the FDA for any human indication. Stealth BioTherapeutics has sought approval for Barth syndrome and received a Complete Response Letter from the agency. Products sold online are labeled as research chemicals for laboratory use only.
What are the most common SS-31 peptide side effects?
In clinical trials, the most frequently reported side effects were injection site reactions, itching, hives, nausea, headache, diarrhea, and fatigue. Most were mild to moderate and resolved without treatment. Any new or severe symptom should be evaluated by a healthcare professional.
Does SS-31 nasal spray work?
There is no published human trial of intranasal elamipretide, so its absorption and effects are unknown. Peptides of this size are generally absorbed poorly through the nasal lining without an absorption enhancer. Sellers making strong efficacy claims for a nasal spray are going beyond the available evidence.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.